Hoffman La Roche completed the first phase of construction for a vitamins and minerals premix plant at Isando, Republic of South Africa, in June 2002.
The facility was inaugurated by Hoffman La Roche’s vitamins and fine chemicals division head Dr Marcus Altwegg on 25 June 2002.
In early July 2002, Roche instigated negotiations with DSM for the sale of its entire vitamin and premix manufacturing business. It was sold in late 2002 in a deal worth $2.24bn. Roche received 2.24 million shares in DSM.
This final price was reduced by €200m after Roche was found guilty of operating a price-fixing cartel for vitamin and nutritional products. The firm was fined in the US and Europe and also retained liability for court costs and compensation arising from these legal issues.
Roche holds a 42% market share worldwide in the vitamin and prefix manufacturing business and is the world’s leading supplier of vitamins and carotenoids. DSM had no other vitamin and premix business interest and so avoided monopoly investigations by European government bodies.
The facility manufactures vitamin premixes for the food and pharmaceutical industry in South Africa and surrounding African nations such as Nigeria, Ghana and Kenya.
The facility works in cooperation with UNICEF in producing the vitamin premixes necessary to fortify basic foodstuffs in under-developed African nations.
Construction of the premix plant at Isando was started in the first half of 2000. The new facility entered full commercial-scale production a little later than first planned in 2002. The plant was constructed at an estimated cost of 30m Rand ($2.7m).
This facility was the first phase of a larger project. Completed in 2004, the subsequent phase manufactures vitamin premixes for animal nutrition.
The total value of the entire project is estimated at $6m. The capacity of the first phase facility was 1,400t per year. The much larger second phase took production to 3,000t per year by mid-2004.
In the pharmaceutical industry, vitamins are used in supplement preparations such as tablets or capsules.
Since companies have begun moving away from using single vitamins to fortify their products and towards multiplicity, the services of premix plants have been in great demand. This has strengthened the premix industry considerably.
It is for this reason that a number of premix plant projects have been initiated by leading pharmaceuticals suppliers, including the Roche premix plants in Poland and El Salto, Mexico. The company has a total of 48 premix facilities around the world.
Problems have arisen in the vitamins market in recent years due to increased competition from vitamin manufacturers in China that can produce cheaper products and also by the increasing cost of raw materials. The price increases are linked to the price of crude oil.
DSM is looking to boost revenue by producing products from plant raw materials. A recent success story is Teavigo, which is a purified, concentrated form of the green tea active epigallocatechin gallate (EGCG) known as a potent antioxidant. This was developed by Roche prior to the sale to DSM.
Teavigo has achieved generally recognised as safe (GRAS) status from the US Food and Drug Administration (FDA) and is now being incorporated into a wide range of foods. Prior to this, the compound was incorporated into commercial foodstuffs in South Africa.
Vitamin and mineral deficiencies prevent some 30% of the world’s population from achieving their full mental and physical potential. This phenomenon is often referred to as hidden hunger.
Food fortification is designed to combat the hidden hunger problem by delivering foods rich in micronutrients to large populations, especially in developing countries. The plant at Isando can now produce the necessary vitamin A, B and mineral premixes to supplement basic foodstuffs and reduce the hidden hunger problem. The plant is responsible for the supply of vitamins and nutritional mixes to its neighbouring countries in Africa.
Taysha Gene Therapies will build a new current Good Manufacturing Practices (cGMP) gene therapy manufacturing facility in Durham, North Carolina,…
Cytiva opened a new facility for manufacturing Xcellerex XDR bioreactors in Shrewsbury, Massachusetts, US, in December 2020. The new manufacturing…
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific is developing a new current good manufacturing practice (cGMP) facility in Carlsbad, California to expand its clinical…